MedTrace Logo

CD-NP in Subjects With Stable Chronic Heart Failure

NCT00620308 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2012-09-10

No results posted yet for this study

Summary

This human physiologic study will evaluate the effects of a new drug called CD-NP in individuals with stable chronic heart failure, with a focus on evaluating responses of the kidneys and the hormonal system.

Conditions

  • Stable Chronic Heart Failure

Interventions

DRUG

CD-NP

One of two dosage levels (20 ng/kg/min and another level to be finalized) as a continuous intravenous infusion for four hours

DRUG

Placebo

Dextrose 5% in water (the vehicle)

Sponsors & Collaborators

Principal Investigators

  • John C. Burnett, Jr., MD · Mayo Foundation

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00620308 on ClinicalTrials.gov